Recruiting PHASE2 INTERVENTIONAL 1-arm NCT05941325

A Single-arm, Open-label, Single-center Prospective Study of Fruquintinib Combined With Envafolimab in the Treatment of Advanced or Unresectable Locally Advanced Bone and Soft Tissue Sarcoma

Shanghai Sixth People's Hospital

Sponsor: Shanghai 6th People's Hospital

Conditions Advanced or Unresectable Locally Advanced Bone and Soft Tissue Sarcoma

Updated 5 times since 2023 Last updated: May 14, 2025 Started: Apr 1, 2023 Primary completion: Dec 1, 2025 Completion: Dec 1, 2026

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT05941325, this PHASE2 trial focuses on Advanced or Unresectable Locally Advanced Bone and Soft Tissue Sarcoma and remains actively recruiting participants. Sponsored by Shanghai 6th People's Hospital, it has been updated 5 times since 2023, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

5 versions recorded

Jun 2025 — Present [monthly]

Recruiting PHASE2
Sep 2024 — Jun 2025 [monthly]

Recruiting PHASE2
Jul 2024 — Sep 2024 [monthly]

Recruiting PHASE2
May 2024 — Jul 2024 [monthly]

Recruiting PHASE2

Status: Not Yet Recruiting → Recruiting
Aug 2023 — May 2024 [monthly]

Not Yet Recruiting PHASE2

First recorded

Apr 2023

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Shanghai 6th People's Hospital

Data source: Shanghai 6th People's Hospital

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Shanghai, China